Ovarian cancer statistics, 2018
May 29, 2018A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data. Ovarian Cancer Statistics, 2018 is published early online in CA: A Cancer Journal for Clinicians.
Below are highlights from the report.
- In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States.
- In the U.S., overall ovarian cancer incidence declined by 29% from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000), while mortality declined 33% from 1976 (10.0 per 100,000) to 2015 (6.7 per 100,000).
- Decreases in ovarian cancer incidence has been driven largely by declines in whites that accelerated during the past decade.
- Racial/ethnic differences in ovarian cancer risk are partially explained by known risk factors. Multiple births, use of oral contraceptives, tubal ligation, and oophorectomy reduce risk, while menopausal hormone use increases risk. However, the source of most of the variation remains unknown.
- Declines in ovarian cancer mortality are due to reductions in incidence as well as improvements in treatment.
- The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer.
- Mutations in BRCA1 and BRCA2 account for almost 40% of ovarian cancer cases in women with a family history of the disease.
- Due to a relatively high prevalence of identified genetic mutations, genetic testing is recommended for all women diagnosed with ovarian cancer to inform their medical and reproductive decisions and those of their relatives.
- Incidence of ovarian cancer among women over 65 has generally declined at a continuous rate since at least 1975, likely due to uptake of oral contraceptives, which confer a substantial risk reduction and also likely contributed to the recent declines in older women.
- Among women who use oral contraceptives for five to nine years total, risk is reduced by about 35%.
- Currently, there is no recommended screening test for ovarian cancer, although large scale randomized clinical studies to identify effective screening modalities are ongoing.
- The efficacy of screening for ovarian cancer has not been demonstrated in prospective randomized controlled trials.
- Studies indicate that some women experience persistent nonspecific symptoms in the months prior to diagnosis, including back pain, abdominal distension, pelvic or abdominal pain, difficulty eating or feeling full quickly, vomiting, indigestion, altered bowel habits, or urinary urgency or frequency. Women who experience such symptoms daily for more than a few weeks should seek prompt medical evaluation.
"Although ovarian cancer is not one of the most common cancers, it causes 5 percent of cancer deaths among US women," said Lindsey Torre, MSPH, lead author of the report. "Understanding of the disease has evolved rapidly in recent years; however, much remains to be gained in ovarian cancer research."
-end-
Article: Ovarian Cancer Statistics, 2018 CA: A Cancer J for Clin doi: 10.3322/caac.21456.URL upon publication: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21456
American Cancer Society
Related Ovarian Cancer Articles from Brightsurf:
Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.
Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.
New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.
How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.
New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.
Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.
Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.
Screening for ovarian cancer not recommended
The US Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in women without symptoms and who are not known to be at high risk (such as those who have certain hereditary cancer syndromes that increase the risk for ovarian cancer).
Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.
Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.
New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.
How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.
New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.
Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.
Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.
Screening for ovarian cancer not recommended
The US Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in women without symptoms and who are not known to be at high risk (such as those who have certain hereditary cancer syndromes that increase the risk for ovarian cancer).
Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.